Aura Biosciences, Inc. AURA R2K
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -26.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AURA Aura Biosciences, Inc. R2K | 7.47 | - | $772.30M | - | -74.67% | -95.57% | - | -26.90% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.04M | 28.61M | 27.91M | 27.24M | 34.87M |
| Operating Income | - | - | -3.63M | -5.93M | -8.80M | -8.89M | -12.81M | -13.82M | -16.05M | -19.44M | -20.28M | -20.49M | -22.31M | -22.76M | - | -29.04M | -28.61M | -27.91M | -27.24M | -34.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.74M | -28.33M | -27.63M | -26.96M | -34.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.46M | -26.97M | -26.10M | -25.54M | -33.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 48.00K | 26.00K | 15.00K | 11.00K |
| Net Income | -7.51M | -6.16M | -3.63M | -5.93M | -8.85M | -8.84M | -12.84M | -13.47M | -15.90M | -17.47M | -18.30M | -18.51M | -19.71M | -20.34M | - | -27.48M | -27.02M | -26.13M | -25.56M | -33.69M |
| Diluted EPS | - | - | - | - | -28.53 | -28.33 | -0.44 | -0.46 | -0.54 | -0.46 | -0.48 | -0.48 | -0.40 | -0.41 | -0.42 | -0.55 | -0.47 | -0.40 | - | -0.50 |
| R&D Expense | - | - | 2.85M | 4.18M | 6.63M | 6.37M | 8.28M | 9.51M | 11.29M | 14.40M | 15.12M | 15.43M | 17.05M | 16.88M | 17.04M | 23.34M | 22.88M | 22.18M | - | 27.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 60.30M | 84.99M | 96.12M | 112.79M |
| Operating Income | -22.21M | - | -60.30M | -84.99M | -96.12M | -112.79M |
| EBITDA | - | - | -59.12M | -83.70M | -94.89M | -111.66M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -58.76M | -76.27M | -86.81M | -106.08M |
| Tax Provision | - | - | 0 | 137.00K | 112.00K | 108.00K |
| Net Income | -22.21M | - | -58.76M | -76.41M | -86.92M | -106.19M |
| Diluted EPS | - | - | -1.96 | -1.93 | -1.75 | -1.76 |
| R&D Expense | 18.04M | 25.16M | 42.24M | 65.23M | 73.30M | 90.30M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -26.90% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +27.47% |
| 6 Months: | +22.26% |
| 3 Months: | +26.83% |
| 1 Month: | +11.00% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.10M | - | 223.94M | 255.07M | 182.50M | 169.43M |
| Current Assets | - | - | - | 196.70M | 231.79M | 160.62M | 149.74M |
| Cash & Equivalents | - | 17.39M | - | 121.58M | 41.06M | 31.69M | 59.52M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.74M | - | 28.35M | 29.23M | 30.53M | 32.52M |
| Current Liabilities | - | 2.66M | - | 10.46M | 12.36M | 14.91M | 18.38M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 20.86M | 19.56M | 18.77M | 17.38M |
| Total Equity | -87.41M | -108.71M | - | 195.58M | 225.85M | 151.97M | 136.91M |
| Shares Outstanding | - | - | - | 37.77M | 49.35M | 50.00M | 63.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.32M | - | -54.60M | -63.85M | -79.81M | -84.74M |
| Investing Cash Flow | -771.00K | - | -67.87M | -113.96M | 68.82M | 35.59M |
| Financing Cash Flow | 10.04M | - | 95.63M | 97.29M | 1.59M | 77.16M |
| Capital Expenditure | -771.00K | - | -1.09M | -709.00K | -1.25M | -447.00K |
| Free Cash Flow | -25.09M | - | -55.70M | -64.56M | -81.06M | -85.19M |
| Net Change in Cash | - | - | -26.84M | -80.52M | -9.39M | 28.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 20.4% | - | -30.0% | -33.8% | -57.2% | -77.6% |
| ROCE % | -114.2% | - | -28.2% | -35.0% | -57.4% | -74.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Matrix Capital Management Company LP | 6.70% | 6.92M | $51.71M |
| 2 | Frazier Life Sciences Management, L.P. | 4.93% | 5.10M | $38.10M |
| 3 | Adage Capital Partners GP L.L.C. | 4.72% | 4.88M | $36.46M |
| 4 | Long Focus Capital Management, LLC | 4.47% | 4.62M | $34.51M |
| 5 | Suvretta Capital Management, LLC | 4.23% | 4.37M | $32.67M |
| 6 | Blackrock Inc. | 3.47% | 3.59M | $26.79M |
| 7 | Medicxi Ventures Management (Jersey) Ltd | 2.94% | 3.04M | $22.71M |
| 8 | Vanguard Capital Management LLC | 2.17% | 2.24M | $16.76M |
| 9 | Nantahala Capital Management, LLC | 2.05% | 2.12M | $15.82M |
| 10 | Franklin Resources, Inc. | 2.00% | 2.07M | $15.48M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AURA